Mutators among CTX-M beta-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance

Matthew J Ellington, David M Livermore, Tyrone L Pitt, Lucinda M C Hall, Neil Woodford

Research output: Contribution to journalArticlepeer-review

43 Citations (Scopus)


Fosfomycin is a possible oral treatment for lower urinary tract infections caused by Escherichia coli with CTX-M extended-spectrum beta-lactamases but is vulnerable to mutational resistance. Hypermutability among natural E. coli populations might facilitate the emergence of resistance to fosfomycin. We therefore examined the prevalence of mutators amongst urinary isolates of E. coli producing CTX-M beta-lactamases.
Original languageEnglish
Pages (from-to)848-52
Number of pages5
JournalJournal of Antimicrobial Chemotherapy
Issue number4
Publication statusPublished - Oct 2006


  • Anti-Bacterial Agents
  • Drug Resistance, Bacterial
  • Escherichia coli
  • Escherichia coli Infections
  • Fosfomycin
  • Humans
  • Microbial Sensitivity Tests
  • Mutation
  • Urinary Tract Infections
  • beta-Lactamases

Cite this